-
It is expected to treat squamous cell carcinoma of the head and neck. The anti-PD-1 antibody
Time of Update: 2019-10-19
MSD today announced that the European Drug Administration's Committee on human medicinal products (CHMP) recommended approval of two options of keytruda (anti PD-1 therapy of MSD
-
Objective remission rate 77.8%! Cornerstone pharmaceutical anti-PD-L1 in patients with esophageal squamous cell carcinoma positive data
Time of Update: 2019-09-20
Suzhou September 19, 2019 / Meitong news agency / -- Cornerstone Pharmaceutical (Suzhou) Co., Ltd
(hereinafter referred to as "cornerstone pharmaceutical" or "company
-
Cell culture bottle Selection Guide
Time of Update: 2019-07-03
Polyester caps are designed (when unscrewed) for use in open systems that require gas exchange.
-
Keji biological is pleased to obtain the clinical trial permission of GPC3 targeting car-t cells for the treatment of GPC3 positive solid tumors
Time of Update: 2019-01-29
January 28, 2019 / Meitong news agency / -- carsgen therapeutics, a R & D enterprise of car-t cell immunotherapy, today announced that the company is developing products
-
The combination of bavencio and inlyta has achieved positive results in the phase 3 clinical trial of advanced renal cell carcinoma
Time of Update: 2018-09-12
Today, Merck KGaA and Pfizer jointly announced that the combination therapy composed of bavencio (avelumab) and inlita (axitinib) significantly improved the progression free survival (PFS) of patients in the phase 3 clinical trial for advanced renal cell carcinoma (RCC) (
-
Scientists have found that acyclic vitamin A can selectively prevent cancer stem cells from producing new tumors
Time of Update: 2018-04-26
The team studied the transcriptome of cells exposed to acyclic vitamin A and found that they had low expression of MYCN compared with untreated cells, which is usually expressed in tumors and associated with poor prognosis.
-
The results showed that ensartinib was effective and well tolerated in patients with ALK positive non-small cell lung cancer
Time of Update: 2018-04-13
According to the data of phase I / II study released at the 2016 ESMO Conference ( most of the non-small cell lung cancer patients who have not used clozatinib are effective in the treatment of ensortinib.
-
Lok positive non-small cell lung cancer with diagnosis approved today
Time of Update: 2017-06-02
Source: Wuxi apptec 2017-06-02 today, Roche announced that the FDA of the United States has approved Ventana ALK (d5f3) CDX test kit as a concomitant diagnosis
-
Novartis zykadia is approved for first-line treatment of ALK positive non-small cell lung cancer
Time of Update: 2017-05-31
The first-line approval of zykadia for ALK positive metastatic NSCLC demonstrates our commitment to cancer patients.
-
PNAs: new simple protein has positive effect on cell function
Time of Update: 2015-09-14
Scientists at Yale University have developed simple new proteins, which have little chemical diversity, but still play an amazing role in cell function, making cells just like
-
Selection and application of ultrasonic cell breaker
Time of Update: 2013-11-28
In use, the ultrasonic generator circuit converts 50 / 60Hz power supply into 18-21khz high-frequency and high-voltage power, so a large amount of heat will be produced in the process of crushing, which is generally broken in the ice bath.
-
Xalkori is still not recommended for ALK positive non-small cell lung cancer by nice final guidelines
Time of Update: 2013-09-30
September 29, 2013 12:11 source: Ding Xiangyuan UK National Health and Medical Quality Standards Agency (NICE) released the final use guidance plan for xalkori, a Pfizer drug
-
The new nice draft guidelines do not recommend the use of clozatinib in the treatment of ALK positive non-small cell lung cancer
Time of Update: 2013-08-20
2013-08-19 source: Ding Xiangyuan, in the final draft of the new lung cancer medication guidelines issued by nice, does not recommend the use of crazotinib from Pfizer
